Literature DB >> 6089991

Hepatic artery infusion of 5-fluorouracil and mitomycin C in cholangiocarcinoma and gallbladder carcinoma.

G W Smith, R M Bukowski, J S Hewlett, C W Groppe.   

Abstract

Eleven patients with histologically proven cholangiocarcinoma and gallbladder carcinoma were treated with hepatic artery infusion (HAI) of 5-fluorouracil (5-FU) and mitomycin C (Mito-C). Catheters were placed percutaneously through the femoral artery. The schedule used was 5-FU 1200/mg/m2/day given as a continuous infusion for 4 days, plus Mito-C 6 mg/m2 on days 1 and 4. Courses were repeated every 4 weeks. Complete responses (CR) occurred in one patient (9%), and partial response (PR) occurred in six patients (55%). Median survival for all patients from the start of the first treatment was 12.5+ months. Median duration of the response was 3.0 months. Median survival of the patients with gallbladder carcinoma was 12.5 months, and for patients with cholangiocarcinoma has not yet been reached. Drug toxicity was mild, and morbidity of the HAI was minimal. Further trials of chemotherapy in these two neoplasms are warranted.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6089991     DOI: 10.1002/1097-0142(19841015)54:8<1513::aid-cncr2820540806>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  [Intraductal chemotherapy of bile duct cancer with 5-fluorouracil].

Authors:  H J Schmeck; E Bartels; C H Viets; W Arnold
Journal:  Klin Wochenschr       Date:  1986-08-01

Review 2.  Management of unresectable intrahepatic cholangiocarcinoma: how do we decide among the various liver-directed treatments?

Authors:  Eugene J Koay; Bruno C Odisio; Milind Javle; Jean-Nicolas Vauthey; Christopher H Crane
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

3.  Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?

Authors:  Nancy E Kemeny; Lawrence Schwartz; Mithat Gönen; Adam Yopp; David Gultekin; Michael I D'Angelica; Yuman Fong; Dana Haviland; Alexandra N Gewirtz; Peter Allen; William R Jarnagin
Journal:  Oncology       Date:  2011-06-14       Impact factor: 2.935

Review 4.  The role of chemotherapy in the treatment of bile duct cancer.

Authors:  R A Oberfield; R L Rossi
Journal:  World J Surg       Date:  1988-02       Impact factor: 3.352

Review 5.  Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings.

Authors:  Mohammed Saleh; Mayur Virarkar; Vlad Bura; Raul Valenzuela; Sanaz Javadi; Janio Szklaruk; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11

6.  High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.

Authors:  K Habara; T Ajiki; T Kamigaki; T Nakamura; Y Kuroda
Journal:  Jpn J Cancer Res       Date:  2001-10

7.  Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.

Authors:  J W Valle; H Wasan; P Johnson; E Jones; L Dixon; R Swindell; S Baka; A Maraveyas; P Corrie; S Falk; S Gollins; F Lofts; L Evans; T Meyer; A Anthoney; T Iveson; M Highley; R Osborne; J Bridgewater
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

8.  Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).

Authors:  Marianne Sinn; Annett Nicolaou; Jens Ricke; Pjotr Podrabsky; Daniel Seehofer; Bernhard Gebauer; Maciej Pech; Peter Neuhaus; Bernd Dörken; Hanno Riess; Bert Hildebrandt
Journal:  BMC Gastroenterol       Date:  2013-08-09       Impact factor: 3.067

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.